Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD-6277 in T2DM
NCT05666128Phase 2Completed
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HD-6277 in type 2 diabetes mellitus (T2DM), sponsored by Hyundai Pharmaceutical Co., Ltd.. Started Jun 2022; status: completed.
02
Drugs
HD-6277
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05666128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666128.